alexa Safety and Efficacy of Medications in Researches | Open Access Journals
Journal of Osteoarthritis
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Safety and Efficacy of Medications in Researches

Tagreed Altaei D*

Department of Oral diagnosis, Pharmacology and Toxicology, College of Dentistry, Hawler Medical University, Iraq

*Corresponding Author:
Tagreed Altaei D
Department of Oral diagnosis Pharmacology and Toxicology College of Dentistry
Hawler Medical University, Iraq
Tel: 00964750 4941834
E-mail:
[email protected]

Received date: October 29, 2015; Accepted date: October 31, 2015; Published date: January 27, 2016.

Citation: Altaei T (2016) Safety and Efficacy of Medications in Researches. J Ost Arth 1:e102. doi: 10.4172/joas.1000e102

Copyright: © 2016 Altaei TD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Osteoarthritis

Keywords

Safety; Efficacy

Introduction

Systemic and topical dosage of all medications has adverse effects, adverse drug reactions, and drug interactions. The goal is to protect clinical trial participants and patients receiving marketed products from the potentially adverse effects of pharmaceuticals.

Importance of primary and secondary end points

Many studies mentioned the efficacy and safety of the tested drug, but there is no efficacy or safety parameters were found. No description of the studied parameters was neither found, nor any demographic data concerning the enrolled patients. Safety studies are those studies that investigate the potential unwanted pharmacodynamics effects of a substance on the physiological functions using the therapeutic level and above. Any clear correlation between response and concomitant treatment or between response and patient's medical history and attendant diseases should be elucidated. The means of obtaining adverse-event data (volunteered, checklist, or questioning), as should any specific rating scale(s) used, and any precisely planned follow-up method for adverse effects or reactions should be described. The primary measurements and endpoints used to determine efficacy should be precisely specified, it is preferred to examine the dose response.

Does the demographic data effects on the results?

The concentrations of drugs must be measured regarding the sample collection times and periods in relation to the drug administration time should be described. Also relation of drug administration and sampling to the ingestion of food, to posture, and the possible actions of concomitant medication/caffeine/nicotine/alcohol should be elucidated[1]. The measured biological sample, the handling of samples, and the method of assessments used should be described. In addition to that, group data for the critical demographic, baseline characteristics of the subjects or patients, and factors arising during the study that could affect the response to treatment, should be presented. Comparison between the treatment groups for all characteristics should be displayed, also disease factors, relevant previous treatment, and concomitant treatment, factors that affect response to treatment (e.g., weight, body-mass index, lifestyle, renin status, antibody levels, metabolic status).

Did the dose prescribed calculate according to the weight of each patient?

This is an important issue in prescribing systemic pharmaceutical preparations. The dose must correspond to the weight of the patient, and mentioned in research as mg/kg.

How is the efficacy analysed?

Efficacy study is assessed according to level and method of blinding/ masking [e.g., open, double-blind, single-blind, blinded evaluators, and unblinded patients and/or investigators]. Other methods of assessment include class of control(s) [e.g., placebo, no treatment, active drug, and dose-response], and study configuration [parallel, crossover] [2].  Another method to criterion efficacy is the method of assignment to treatment [randomization, stratification]. The specific efficacy and safety variables to be assessed and laboratory analysis to be proceeded, their schedule; days of study, time of day, relation to meals, and the timing of critical measures in relation to the administration of test drug, the methods for measuring, and the investigator responsible for the measurements should be described. Characterization of the criteria for determining the efficacy; Treatment groups should be compared for all critical measures of efficacy [primary and secondary endpoints; any pharmacodynamics endpoints], in addition to the benefit/risk assessment(s) for each patient must utilized, and scale score of categorical responses. Some studies mentioned that 90-95% improvement, with no significant complications. Such comparison put the study under bias risk, and false results.

Safety study

Assessment of safety-related data can be considered at three levels: First, the extent of exposure [dose, duration, patients’ number] should be tested to determine the degree to which safety can be assessed. Second, more common adverse effects and lab tests changes should be clarified, classified, compared between treatment groups, and analysed for factors that may affect the frequency of adverse reactions or events, that could include time dependence, relation to demographic characteristics, and relation to dose or drug concentration. Finally, serious adverse reactions and other significant adverse events should be identified by close examination of patients. Duration of exposure to any dose can be expressed as a median or mean, more than one month to six months. The numbers exposed to the test drug for the various durations should be broken down by age, sex, and racial subgroups, and any other pertinent subgroups, such as groups defined by disease, disease severity, or concurrent illness.

Adverse events occurring after initiation of study therapy (including events related to the underlying disease or represent concomitant illness) should be clarified and discussed, and should include changes in vital signs and any laboratory parameters changes that were considered serious adverse events or significant adverse reactions. [3]Each event may then be divided into severity categories (e.g., mild, moderate, severe). Other method is divide the adverse events into those considered at least possibly related to administered drug and those considered not related, or use another causality scheme (e.g., unrelated or possibly, probably, or definitely related).

The listing should be prepared by investigator and by treatment group and should include the following information: patient identifier, age, race, sex, weight, height, location of case report forms, the adverse event, duration of the adverse event, severity, seriousness, action taken (none, dose reduced, treatment stopped, specific treatment), results and causal relationship assessment (e.g., related/not related), date of onset or date of discovered, timing of onset of the adverse event of the test drug, study treatment at the time of event, test drug dose in mg/kg at time of event, duration of test drug therapy, concomitant medications, all these data should be determined and described.

Vital signs, other physical findings, and other observations related to safety should be analyzed and presented in a way similar to laboratory variables. The clinical relevance of the results should be discussed in the light of other existing data, including any specific benefits or special precautions required for individual subjects. Information on the primary and secondary pharmacodynamics properties of the drug used may contribute to the safety evaluation for potential adverse effect(s) in humans and should be considered along with the findings of safety studies.

Conclusion

Safety and efficacy of any drug for the treatment of any disease is very important. The research work will be weak by the presence of bias, the overarching assumptions they occasionally made, prejudice, and misinformation, can lead to non-accurate data to the readers, which open the door for the usage of these medications without specialist consultation that leads to adverse drug effects or adverse reactions. In studies a better measures must be developed, and larger samples must be used to identify and improve the safety and efficacy of all investigated drugs, as well as rare and more severe side effects that may be associated with its usage. Because of the risk of bias, an adequately sized, double blind placebo-controlled trail is needed to confirm the efficacy and safety of tested medications in the treatment of diseases in both genders.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 7763
  • [From(publication date):
    January-2016 - Aug 23, 2017]
  • Breakdown by view type
  • HTML page views : 7714
  • PDF downloads :49
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords